

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of identifying a cancer cell selected from the group consisting of colon cancer, thyroid cancer and renal cancer, comprising:
 - a) measuring expression of a nucleic acid encoding an antileukoprotease polypeptide in a test sample, wherein the nucleic acid comprises the nucleic acid sequence of SEQ ID NO:1 or the nucleic acid encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2; and
 - b) comparing the expression of the nucleic acid of step (a) in the test sample to the expression of a reference nucleic acid encoding an antileukoprotease polypeptide in a cancer reference profile,
wherein a similarity between the comparable level of expression of the nucleic acid of step (a) in the test sample and expression of the reference nucleic acid in the reference profile indicates the presence of a cancer cell in the test sample.
2. (Currently Amended) The method of claim 1, wherein the cancer is selected from the group consisting of ovarian cancer, thyroid cancer, and renal cancer.
3. (Currently Amended) The method of claim 2-claim 1, wherein the cancer is ovarian colon cancer.
4. (Currently Amended) A method of identifying a cancer cell selected from the group consisting of colon cancer, thyroid cancer and renal cancer comprising:
 - a) measuring expression of a nucleic acid encoding an antileukoprotease polypeptide in a test sample, wherein the nucleic acid comprises the nucleic acid sequence of SEQ ID NO:1 or the nucleic acid encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2; and

b) comparing the expression of the nucleic acid of step (a) in the test sample to the expression of a reference nucleic acid encoding an antileukoprotease polypeptide in a normal reference profile,
wherein an increase in expression of the nucleic acid of step (a) in the test sample compared to expression of the reference nucleic acid in the normal reference profile indicates the presence of a cancer cell in the test sample.

5. (Currently Amended) The method of claim 4, wherein the cancer is ~~selected from the group consisting of ovarian cancer, thyroid cancer, and renal cancer.~~

6. (Currently Amended) The method of ~~claim 5~~ claim 4, wherein the cancer is ovarian colon cancer.

7. (Cancelled)

8. (Cancelled)

9. (New) The method of claim 1, wherein said cancer is renal cancer.

10. (New) The method of claim 4, wherein said cancer is renal cancer.